Abstract
In this paper, the authors express their views on a range of topics related to data monitoring committees (DMCs) for adaptive trials that have emerged recently. The topics pertain to DMC roles and responsibilities, membership, training, and communication. DMCs have been monitoring trials using the group sequential design (GSD) for over 30 years. While decisions may be more complicated with novel adaptive designs, the fundamental roles and responsibilities of a DMC will remain the same, namely, to protect patient safety and ensure the scientific integrity of the trial. It will be the DMC’s responsibility to recommend changes to the trial within the scope of a prespecified adaptation plan or decision criteria and not to otherwise recommend changes to the study design except for serious safety-related concerns. Nevertheless, compared with traditional data monitoring, some additional considerations are necessary when convening DMCs for novel adaptive designs. They include the need to identify DMC members who are familiar with adaptive design and to consider possible sponsor involvement in unique situations. The need for additional expertise in DMC members has prompted some researchers to propose alternative DMC models or alternative governance model. These various options and authors’ views on them are expressed in this article.
Similar content being viewed by others
References
European Medicines Agency. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. 2007. http://www.emea.europa.eu/pdfs/human/ewp/245902enadopted.pdf. Accessed October 18, 2007.
US Food and Drug Administration. Draft guidance for industry: adaptive design clinical trials for drugs and biologics. February 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf.
Ellenberg S, Fleming T, DeMets D. Data Monitoring Committees in Clinical Trials: A Practical Perspective. New York, NY: Wiley; 2002.
US Food and Drug Administration. Guidance for clinical trial sponsors on the establishment and operation of clinical trial data monitoring committees. March 2006. http://www.fda.gov/downloads/Regulatoryinformation/Guidances/ucm127073.pdf.
European Medicines Agency. Guideline on data monitoring committees. 2006. July 27, 2005. http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003635.pdf.
Wang SJ, Hung JHM, O’Neill R. Adaptive design clinical trials and trial logistics models in CNS drug development. Eur Neuropsychopharmacol. 2011;21:159–166.
Shen J, Preskorn S, Dragalin V, et al. How adaptive trial designs can increase efficiency in psychiatric drug development: a case study. Innov Clin Neurosci. 2011;8(26):26–34.
Gallo P, Fardipour P, Dragalin V, Littman GS, Bretz F. Data monitoring in adaptive dose-ranging trials. Stat Biopharm Res. 2010;2(4):513–521.
Chow SC, Corey R, Lin M. On the independence of data monitoring committee in adaptive design clinical trials. J Biopharm Stat. 2012;22(4):853–867.
Gallo P. Confidentiality and trial integrity issues for adaptive designs. Drug Inf J. 2006;40:445–450.
Califf RM, Harrington RA, Blazing MA. Premature release of data from clinical trials of ezetimibe. N Engl J Med. 2009;361(7):712–717.
Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86:97–100.
Gaydos B, Anderson K, Berry DA, et al. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Inf J. 2009;43(5):539–565.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Antonijevic, Z., Gallo, P., Chuang-Stein, C. et al. Views on Emerging Issues Pertaining to Data Monitoring Committees for Adaptive Trials. Ther Innov Regul Sci 47, 495–502 (2013). https://doi.org/10.1177/2168479013486996
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479013486996